Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 6, 2001, Pages 2428-2436

  Gill, Sabrina ^a   Taylor, Ann E ^a   Martin, Kathryn A ^a   Welt, Corrine K ^a   Adams, Judith M ^a   Hall, Janet E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; GONADORELIN; HYDROXYPROGESTERONE; INSULIN; TESTOSTERONE;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; OLIGOMENORRHEA; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE;

ADULT; BODY MASS INDEX; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSULIN; LUTEINIZING HORMONE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROGNOSIS; PULSATILE FLOW;

FALLOPIA;

EID: 0034970249     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.6.2428     Document Type: Article

References (56)

1. Diagnostic criteria for polycysfic ovary syndrome: Towards a rational approach
2. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern US: A prospective study
3. Polycystic ovary syndrome
4. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease
5. Insulin, androgens and obesity in women with and without polycystic ovary syndrome: Heterogenous group of disorders
6. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies
7. Clinical and laboratory predictors of clomiphene response
8. Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: The difference between responders and nonresponders
9. Ovulation induction with pulsatile luteinizing releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: Clinical results
10. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH
11. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome
12. Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome
13. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotropin
14. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders
15. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women
16. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome
17. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea
18. Gonadotropin-releasing hormone analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH
19. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: Indirect evidence for partial gonadotroph desensitization
20. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
21. Clinical assessment of body hair growth in women
22. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism
23. Differences between the tolbutabmide-boosted and the insulin-modified minimal model protocols
24. Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: Effects of dosage
25. Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone
26. Inhibin A and inhibin B responses to gonadotropin withdrawal depend on stage of follicle development
27. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome
28. The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men
29. Neuroendocrine regulation of the corpus luteum in the human
30. A comparison of 13 different immunometric assay kits for gonadotropins: Implications for clinical investigation
31. Ovarian 17-hydroxyprogesterone hyperresponsiveness to GnRH agonist challenge in women with polycystic ovary syndrome is not mediated by gonadotropin hypersecretion: Evidence from GnRH agonist and human chorionic gonadotropin stimulation testing
32. Inhibin B in males with gonadotropin-releasing hormone deficiency: Changes in serum concentration after short term physiologic GnRH replacement
33. Impact of binge eating on metabolic and leptin dynamics in normal young women
34. Episodic luteinizing hormone secretion in man: Pulse analysis, clinical interpretation, and physiologic mechanism
35. Free α-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies
36. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test
37. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: Prognostic factors and clinical results in 600 cycles
38. One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulation
39. Body weight, body mass index, and age: Predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome
40. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility
41. Free androgen index and leptin are the most prominant endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility
42. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction
43. Metabolic parameters that predict response to clomiphene citrate in obese oligo-ovulatory women
44. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene
45. Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease
46. How good a marker is insulin level for insulin resistance?
47. Ovarian 17-OH progesterone hyperresponsiveness predicts hyperinsulinemia in women with polycystic ovary syndrome
48. Both inhibin A and B respond to exogenous follicle-stimulating hormone in the follicular phase of the human menstrual cycle
49. Differential regulation of inhibin A and inhibin B by LH, FSH, and stage of follicle development
50. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce monoovulation
51. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of neuroendocrine and androgen dynamics
52. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: Characterization and management
53. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease
54. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropin releasing hormone
55. Androgen stimulates early stages of follicular growth in the primate ovary
56. Hormonal effects of flutamide in young women with polycystic ovary syndrome